GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » Cyclically Adjusted Revenue per Share

Hanall Biopharma Co (XKRX:009420) Cyclically Adjusted Revenue per Share : ₩2,231.81 (As of Dec. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Hanall Biopharma Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Hanall Biopharma Co's adjusted revenue per share for the three months ended in Dec. 2023 was ₩618.011. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩2,231.81 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Hanall Biopharma Co's average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -4.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Hanall Biopharma Co was 1.30% per year. The lowest was -9.10% per year. And the median was -5.60% per year.

As of today (2024-04-30), Hanall Biopharma Co's current stock price is ₩35350.00. Hanall Biopharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was ₩2,231.81. Hanall Biopharma Co's Cyclically Adjusted PS Ratio of today is 15.84.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hanall Biopharma Co was 19.87. The lowest was 3.91. And the median was 10.30.


Hanall Biopharma Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Hanall Biopharma Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co Cyclically Adjusted Revenue per Share Chart

Hanall Biopharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,518.21 2,148.25 2,007.29 2,118.20 2,231.81

Hanall Biopharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,118.20 2,147.68 2,184.41 2,229.20 2,231.81

Competitive Comparison of Hanall Biopharma Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Hanall Biopharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hanall Biopharma Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hanall Biopharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hanall Biopharma Co's Cyclically Adjusted PS Ratio falls into.



Hanall Biopharma Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hanall Biopharma Co's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=618.011/118.8477*118.8477
=618.011

Current CPI (Dec. 2023) = 118.8477.

Hanall Biopharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 491.792 99.253 588.882
201406 502.491 99.353 601.088
201409 501.328 99.608 598.162
201412 512.215 99.098 614.297
201503 517.324 99.720 616.554
201506 570.616 100.050 677.825
201509 391.944 100.110 465.305
201512 404.066 100.220 479.169
201603 419.347 100.560 495.609
201606 399.451 100.790 471.017
201609 387.702 101.460 454.144
201612 423.648 101.560 495.762
201703 368.826 102.850 426.195
201706 414.781 102.610 480.419
201709 482.225 103.490 553.786
201712 403.355 102.990 465.461
201803 431.176 104.100 492.260
201806 442.199 104.130 504.699
201809 470.093 105.650 528.817
201812 436.661 104.350 497.328
201903 475.354 104.490 540.671
201906 583.198 104.880 660.867
201909 548.929 105.200 620.142
201912 512.618 105.120 579.561
202003 433.166 105.540 487.785
202006 440.772 104.870 499.521
202009 434.671 106.200 486.437
202012 422.734 105.765 475.023
202103 540.547 107.357 598.402
202106 459.945 107.579 508.125
202109 494.693 108.759 540.581
202112 491.235 109.676 532.313
202203 579.574 111.806 616.077
202206 679.653 114.083 708.040
202209 565.093 114.831 584.858
202212 676.183 115.200 697.592
202303 568.247 116.550 579.452
202306 817.068 117.140 828.980
202309 650.371 119.111 648.932
202312 618.011 118.848 618.011

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Hanall Biopharma Co  (XKRX:009420) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hanall Biopharma Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=35350.00/2231.81
=15.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hanall Biopharma Co was 19.87. The lowest was 3.91. And the median was 10.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Hanall Biopharma Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Hanall Biopharma Co (XKRX:009420) Business Description

Traded in Other Exchanges
N/A
Address
12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co (XKRX:009420) Headlines

No Headlines